Development and in-vitro evaluation of modified release tablets including ethylcellulose microspheres loaded with diltiazem hydrochloride

Sengel C. T., HASÇİÇEK C., Gonul N.

Journal of Microencapsulation, cilt.23, sa.2, ss.135-152, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 2
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1080/02652040500286474
  • Dergi Adı: Journal of Microencapsulation
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.135-152
  • Anahtar Kelimeler: diltiazern hydrochloride, Kollidon((R))SR, Compritol((R))888 ATO, ethylcellulose microspheres, tablets, DIRECT COMPRESSION, MICROCAPSULES, MICROPARTICLES, FORMULATION, PARAMETERS, SULFATE, AGENTS
  • Ankara Üniversitesi Adresli: Evet

Özet

In this study, development of modified release tablet formulations containing diltiazem hydrochloride-loaded microspheres to be taken once rather than two or three times a day was attempted. For this purpose, ethylcellulose microspheres were prepared by emulsion-solvent evaporation technique. The influence of emulsifier type and drug/polymer ratio on production yield, encapsulation efficiency, particle size, surface morphology and in-vitro release characteristics of the microspheres was evaluated. Suitable microspheres were selected and tabletted using different tabletting agents, Ludipress®, Cellactose®80, Flow-Lac®100 and excipients Compritol®888 ATO, Kollidon®SR. Tablets were evaluated from the perspective of physical and in-vitro drug release characteristics. It was seen that type and ratio of the excipients played an important role in the tabletting of the microspheres. As a result, two tablet formulations containing 180mg diltiazem hydrochloride and using either Compritol®888 ATO or Kollidon®SR were designed successfully and maintained drug release for 24h with zero order and Higuchi kinetics, respectively. © 2006 Taylor & Francis.